Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05275946 | Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer | completed | Phase 1 | 11 | Osaka UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | terminated | Phase 1 | 75 | CelgeneINDUSTRY | 5 | Apr 20, 2025 | clinicaltrials |
| NCT02913313 |
| A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 101 |
| Bristol-Myers SquibbINDUSTRY |
| 8 |
| Apr 20, 2025 |
| clinicaltrials |
| NCT06532331 | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 87 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 183 | CelgeneINDUSTRY | 6 | Apr 17, 2025 | clinicaltrials |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | active not recruiting | Phase 1 | 28 | Institut de Recherches Internationales ServierOTHER | 5 | Apr 11, 2025 | clinicaltrials |
| NCT03473756 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma(FORT-2) | completed | Phase 1 | 37 | BayerINDUSTRY | 8 | Apr 9, 2025 | clinicaltrials |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | completed | Phase 1 | 67 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 9, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT04317066 | A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) | completed | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT05267470 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)(FORTITUDE-201) | terminated | Phase 1 | 74 | AmgenINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT00979576 | BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03444701 | A Study of E7130 in Participants With Solid Tumors | completed | Phase 1 | 62 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT02834390 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05087992 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 5 | Feb 19, 2025 | clinicaltrials |
| NCT02966548 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT02300298 | Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | completed | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT01214616 | BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 17 | Boehringer IngelheimINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03406871 | Regorafenib and Nivolumab Simultaneous Combination Therapy(REGONIVO) | completed | Phase 1 | 50 | Kohei ShitaraOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT01121588 | Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) | terminated | Phase 1 | 44 | PfizerINDUSTRY | 7 | Jan 23, 2025 | clinicaltrials |
| NCT04171141 | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | terminated | Phase 1 | 79 | PfizerINDUSTRY | 3 | Jan 16, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT04727554 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | AmgenINDUSTRY | 10 | Jan 6, 2025 | clinicaltrials |
| NCT02723955 | Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | completed | Phase 1 | 829 | GlaxoSmithKlineINDUSTRY | 9 | Dec 27, 2024 | clinicaltrials |
| NCT02746081 | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | completed | Phase 1 | 81 | BayerINDUSTRY | 4 | Dec 18, 2024 | clinicaltrials |
| NCT02398747 | Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02675491 | Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors | completed | Phase 1 | 15 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02495233 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | terminated | Phase 1 / Phase 2 | 10 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04079296 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 26, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia(TBI-1501) | active not recruiting | Phase 1 / Phase 2 | 21 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03250325 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | completed | Phase 1 / Phase 2 | 8 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02699515 | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 114 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT06532344 | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer | active not recruiting | Phase 1 | 32 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03945253 | Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Astellas Pharma IncINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials